Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does the addition of lamivudine to peginterferon α-2a sustain response rates in HBeAg-negative hepatitis B?

Nature Clinical Practice Gastroenterology & Hepatology volume 2, pages 12–13 (2005)Cite this article

boxed-textMarcellin P et al. (2004) Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351: 1206–1217

Peginterferon α-2a monotherapy produced better sustained biochemical and virologic responses than lamivudine and should be the first-line therapy for HBeAg-negative chronic hepatitis B

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. EASL International Consensus Conference on Hepatitis B: 13–14 September, 2002, Geneva, Switzerland: consensus statement (long version). J Hepatol 2003; 39 Suppl 1: S3–S25

  2. Hadziyannis SJ et al. (2000) Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen negative chronic hepatitis B. Hepatology 32: 847–851

    Article  CAS  Google Scholar 

  3. Papatheodoridis GV et al. (2001) The long term outcome of interferon alfa treated and untreated patients with HBe-antigen negative chronic hepatitis. J Hepatol 34: 306–313

    Article  CAS  Google Scholar 

  4. Schalm SW et al. (2000) Lamivudine and alfa interferon combination treatment of patients with chronic hepatitis B infection: a randomized trial. Gut 46: 562–568

    Article  CAS  Google Scholar 

  5. Cooksley WGE et al. (2003) Peginterferon alpha 2-a (40kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 10: 298–305

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Minal Chande, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professorial Research Fellow at University of Queensland, Royal Brisbane Hospital, Brisbane, Australia

    Graham Cooksley

Authors
  1. Graham Cooksley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Graham Cooksley.

Ethics declarations

Competing interests

GC has participated in trials sponsored by Roche, Schering-Plough, GlaxoSmithKline, Gilead, Bristol Myers Squibb. He has served on advisory boards for Roche and GlaxoSmithKline.

Glossary

Hepatitis B e ANTIGEN (HBeAg)-NEGATIVE CHRONIC HEPATITIS B

The result of a mutation in the precore or core promoter region of hepatitis B

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cooksley, G. Does the addition of lamivudine to peginterferon α-2a sustain response rates in HBeAg-negative hepatitis B?. Nat Rev Gastroenterol Hepatol 2, 12–13 (2005). https://doi.org/10.1038/ncpgasthep0068

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0068

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing